New Triple Diabetes Medicine for Recently Diagnosed Type 2
Treatments studied
Part of Hormones & metabolism clinical trials.
This study tests a new three-medicine combination to help control blood sugar in people newly diagnosed with type 2 diabetes who haven't been treated yet. The goal is to find out if this combination works better than current options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years old
- Recently diagnosed with type 2 diabetes (within the last year) and not yet treated, or stopped treatment at least 3 months ago
- Blood sugar control level (HbA1c) between 6.5% and 9.0%
- Body mass index (BMI) of 24 or higher
- Kidney function measured as eGFR ≥20 mL/min/1.73 m² (adequate kidney health)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new triple-combination therapy (three diabetes medicines together) for people with newly diagnosed type 2 diabetes who are overweight. The goal is to see if this combination can better control blood sugar and help with weight management.
This study tests a combination of three diabetes medicines (empagliflozin, linagliptin, and metformin) to see if it helps control blood sugar in people with type 2 diabetes. It may be an option if your current treatment isn't working well enough.
This trial tests if newer diabetes medications can reduce heart risk and help achieve diabetes remission in people newly diagnosed with type 2 diabetes. It may be an option if you have not taken diabetes drugs before or stopped them over three months ago, and your blood sugar and weight are in certain ranges.
This trial tests a combination of three diabetes medicines to see if they can quickly get high blood sugar under control in people newly diagnosed with type 2 diabetes. It's designed for those whose HbA1c is 9.0% or higher.
This trial is testing a combination of three diabetes medicines (henagliflozin, retagliptin, and metformin) in people newly diagnosed with type 2 diabetes. The goal is to see if this triple therapy works better for controlling blood sugar compared to standard treatments.
This study looks at the safety and effectiveness of adding a third oral diabetes medicine to your current two-drug combination. It is for adults with type 2 diabetes whose blood sugar is not well controlled on metformin plus one other pill.
Hear when a new Diabetes Mellitus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.